S. Ammoun

发表

G-protein-coupled OX1 Orexin/hcrtr-1 Hypocretin Receptors Induce Caspase-dependent and -independent Cell Death through p38 Mitogen-/Stress-activated Protein Kinase*

H. Wootz, J. Kukkonen, D. Lindholm, 2006, Journal of Biological Chemistry.

OX1 Orexin Receptors Couple to Adenylyl Cyclase Regulation via Multiple Mechanisms*

J. Kukkonen, K. Åkerman, S. Ammoun, 2005, Journal of Biological Chemistry.

Functions of the orexinergic/hypocretinergic system.

J. Kukkonen, K. Åkerman, S. Ammoun, 2002, American journal of physiology. Cell physiology.

Cellular prion protein (PrPC) in the development of Merlin-deficient tumours

C. Hanemann, D. Hilton, S. Ammoun, 2017, Oncogene.

Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

P. Manley, C. Hanemann, S. Ammoun, 2011, Neuro-oncology.

The role of insulin‐like growth factors signaling in merlin‐deficient human schwannomas

C. Carroll, C. Hanemann, E. Ercolano, 2012, Glia.

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

L. Chiriboga, F. Giancotti, Jeffrey C. Allen, 2010, Neuro-oncology.

Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival

C. Hanemann, K. Evans, C. Hanemann, 2014, Oncogene.

Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.

C. Hanemann, E. Ercolano, Lu Zhou, 2011, Neoplasia.

Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival

C. Hanemann, C. Perks, E. Ercolano, 2012, Oncogene.

An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

J. Chernoff, A. Andrews, C. Hanemann, 2017, Cancer research.

OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling.

H. Haas, J. Kukkonen, L. Korhonen, 2006, Molecular endocrinology.

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244

C. Matthies, C. Hanemann, D. Hilton, 2010, Neurobiology of Disease.

Recombinant expression of a selective blocker of M(1) muscarinic receptors.

K. Åkerman, J. Näsman, E. Karlsson, 2000, Biochemical and biophysical research communications.

Distinct recognition of OX 1 and OX 2 receptors by orexin peptides

M. Parmentier, J. Kukkonen, K. Åkerman, 2003 .

PAK kinase regulates Rac GTPase and is a potential target in human schwannomas

J. R. Peterson, J. Chernoff, C. Hanemann, 2009, Experimental Neurology.

Retroviral RNA related to ERV9/MSRV in a human serum: a new sequence variant.

J. Blomberg, S. Ammoun, B. Ryberg, 1999, AIDS research and human retroviruses.

Role of G-protein availability in differential signaling by alpha 2-adrenoceptors.

J. Kukkonen, K. Åkerman, K E Akerman, 2001, Biochemical pharmacology.

The p53/mouse double minute 2 homolog complex deregulation in merlin‐deficient tumours

C. Hanemann, D. Hilton, Lu Zhou, 2015, Molecular oncology.

Expression of c‐Jun and Sox‐2 in human schwannomas and traumatic neuromas

D. Parkinson, C. Hanemann, S. Ammoun, 2013, Histopathology.

Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.

Sylwia Ammoun, Christine Flaiz, Natalia Ristic, 2008, Cancer research.

Kinase Pathway in Human Schwannoma Independent Extracellular Signal-Regulated − Growth Factor Dependent and − Dissecting and Targeting the Growth Factor

Sylwia Ammoun, Christine Flaiz, Natalia Ristic, 2008 .

Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas

K. Kurian, C. Hanemann, M. Jenkinson, 2021, International journal of molecular sciences.

Emerging therapeutic targets in schwannomas and other merlin-deficient tumors

C. Hanemann, S. Ammoun, 2011, Nature Reviews Neurology.

Altered Adhesive Structures and Their Relation to RhoGTPase Activation in Merlin‐Deficient Schwannoma

C. Hanemann, S. Ammoun, Anja Biebl, 2009, Brain pathology.

Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2

D. Evans, C. Hanemann, D. Hilton, 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

Distinct Recognition of OX1 and OX2Receptors by Orexin Peptides

Marc Parmentier, Ramin Shariatmadari, M. Parmentier, 2003, Journal of Pharmacology and Experimental Therapeutics.

The role of insulin-like growth factors signaling in merlin-deficient human

C. Carroll, E. Ercolano, D. Hilton, 2022 .

The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors

E Lasonder, Jurgen Müller, C. Hanemann, 2016, Oncogene.

Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival

K. Evans, C. Hanemann, D. Hilton, 2014, Oncogene.

Axl/Gas6/NFB signalling in schwannoma pathological proliferation, adhesion and survival

K. Evans, S. Ammoun, L. Provenzano, 2022 .

Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma

K. Kurian, D. Parkinson, C. Hanemann, 2021, Cancer Research.

An essential role for the tumor suppressor Merlin in regulating An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis. fatty acid synthesis.

Yin-Ming Kuo, S. Ammoun, D. Stepanova, 2022 .